AMDL Announces Key Anti-Cancer Drug for China
February 12 2007 - 7:27AM
PR Newswire (US)
TUSTIN, Calif., Feb. 12 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, announced today that Jade
Pharmaceuticals, its wholly-owned subsidiary in China, has set up
production and applied for SFDA (China State Food and Drug
Administration) approval to market Docetaxel in China. Docetaxel is
an anti-cancer drug that interferes with the growth of cancer
cells. "There is an enormous need in China for effective and
affordable cancer drugs, with more than 1.6 million new cases of
the disease annually," said Gary Dreher, AMDL CEO. "Docetaxel is
extremely useful because it can treat a broad spectrum of cancers,
including breast cancer, non-small cell lung cancer, stomach cancer
and prostate cancer." Docetaxel currently generates more than $2
billion (USD) in sales globally at a rate increasing 20 percent
annually. This drug currently represents approximately $200 million
(USD) in sales in China. The Jade Pharmaceutical sales network is
uniquely positioned to take advantage of the significant marketing
opportunity in China. "Docetaxel is currently the most popular
anticancer drug in China," Mr. Dreher said. "We are very pleased
that our Chinese subsidiary is now a participant in this crucial
market. This product is obviously synergistic to AMDL's focus of
detecting and treating cancer. The recent successes of Jade
Pharmaceuticals including the introduction of key new products will
be a portion of my presentation at the RedChip Small-Cap Investor
Conference on February 12." The Conference is available live on the
Internet at 1:15 p.m. Pacific at
http://www.modavox.com/events/redchip/0207/room1/ and for 90 days
after the conference at http://www.redchip.com/ . About AMDL AMDL,
Inc., headquartered in Tustin, California, with operations in
Shenzhen, Jaingxi and Jilin China through its wholly owned
subsidiary Jade Pharmaceutical Inc., is an international biopharma
company. AMDL together with Jade engages in the development,
manufacture and marketing of proprietary pharmaceutical and testing
products. More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. Contact: AMDL, Inc. Gary L. Dreher President & CEO
(714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher,
President & CEO, AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/ http://www.redchip.com/
http://www.modavox.com/events/redchip/0207/room1
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024